Yuan Xu1, Fei Teng2, Shi Huang3, Zhengmei Lin2, Xiao Yuan4, Xiaowei Zeng3, Fang Yang5. 1. Department of Stomatology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address: xuyuan@sysucc.org.cn. 2. Department of Operative Dentistry and Endodontics, Guanghua School and Hospital of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, China. 3. Bioenergy Genome Center, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, Shandong, China. 4. Oral Research Center, Qingdao Municipal Hospital, Qingdao, Shandong, China. 5. Oral Research Center, Qingdao Municipal Hospital, Qingdao, Shandong, China. Electronic address: yangf82@sina.com.
Abstract
OBJECTIVE: A growing body of evidence has implicated human oral microbiota in the aetiology of oral and systemic diseases. Nasopharyngeal carcinoma (NPC), an epithelial-originated malignancy, has a complex aetiology not yet fully understood. Chemoradiation therapy of NPC can affect oral microbiota and is usually accompanied by plaque accumulation. Thus, the study aimed to understand the diversity, divergence and development of the oral microbiota in NPC patients and their associated treatment, which might provide useful insights into disease aetiology and treatment side effects. DESIGN: A longitudinal study was designed that included three Chinese adults with NPC. Saliva samples were collected at three time points: prior to the chemoradiation treatment (carcinoma baseline, or CB), 7 months post-treatment (carcinoma-after-therapy phase 1 or CA1) and 12 months post-treatment (carcinoma-after-therapy phase 2 or CA2). Pyrosequencing of the bacterial 16S ribosomal DNA (rDNA) V1-V3 hypervariable region was employed to characterise the microbiota. Saliva samples of three healthy subjects from our former study were employed as healthy controls. Principal coordinates analysis (PCoA), Metastats and random forest prediction models were used to reveal the key microbial members associated with NPC and its treatment programme. RESULTS: (1) In total, 412 bacterial species from at least 107 genera and 13 phyla were found in the saliva samples of the NPC patients. (2) PCoA revealed that not only were the microbiota from NPC patients distinct from those of healthy controls (p<0.001) but also that separation was found on the saliva microbiota between pre- and post-therapy (p<0.001) in the NPC samples. (3) At the genus level and the operational taxonomic unit (OTU) level, Streptococcus was found with lower abundance in NPC samples. (4) Chemoradiation therapy did not incur similar changes in microbiota structure among the three NPC patients; the microbiota in one of them stayed largely steady, while those in the other two showed significant alteration. CONCLUSIONS: This is the first study employing culture-independent techniques to interrogate the phylogenetic diversity, divergence and temporal development of oral microbiota in NPC patients. Our results indicated that certain bacterial taxa might be associated with NPC and that oral microbiota of NPC patients might respond to the chemoradiation therapy in a host-specific manner. Further investigation with larger sample size should help to validate the links between oral microbiota and NPC.
OBJECTIVE: A growing body of evidence has implicated human oral microbiota in the aetiology of oral and systemic diseases. Nasopharyngeal carcinoma (NPC), an epithelial-originated malignancy, has a complex aetiology not yet fully understood. Chemoradiation therapy of NPC can affect oral microbiota and is usually accompanied by plaque accumulation. Thus, the study aimed to understand the diversity, divergence and development of the oral microbiota in NPCpatients and their associated treatment, which might provide useful insights into disease aetiology and treatment side effects. DESIGN: A longitudinal study was designed that included three Chinese adults with NPC. Saliva samples were collected at three time points: prior to the chemoradiation treatment (carcinoma baseline, or CB), 7 months post-treatment (carcinoma-after-therapy phase 1 or CA1) and 12 months post-treatment (carcinoma-after-therapy phase 2 or CA2). Pyrosequencing of the bacterial 16S ribosomal DNA (rDNA) V1-V3 hypervariable region was employed to characterise the microbiota. Saliva samples of three healthy subjects from our former study were employed as healthy controls. Principal coordinates analysis (PCoA), Metastats and random forest prediction models were used to reveal the key microbial members associated with NPC and its treatment programme. RESULTS: (1) In total, 412 bacterial species from at least 107 genera and 13 phyla were found in the saliva samples of the NPCpatients. (2) PCoA revealed that not only were the microbiota from NPCpatients distinct from those of healthy controls (p<0.001) but also that separation was found on the saliva microbiota between pre- and post-therapy (p<0.001) in the NPC samples. (3) At the genus level and the operational taxonomic unit (OTU) level, Streptococcus was found with lower abundance in NPC samples. (4) Chemoradiation therapy did not incur similar changes in microbiota structure among the three NPCpatients; the microbiota in one of them stayed largely steady, while those in the other two showed significant alteration. CONCLUSIONS: This is the first study employing culture-independent techniques to interrogate the phylogenetic diversity, divergence and temporal development of oral microbiota in NPCpatients. Our results indicated that certain bacterial taxa might be associated with NPC and that oral microbiota of NPCpatients might respond to the chemoradiation therapy in a host-specific manner. Further investigation with larger sample size should help to validate the links between oral microbiota and NPC.
Authors: Ivry Zagury-Orly; Nader Khaouam; Jonathan Noujaim; Martin Y Desrosiers; Anastasios Maniakas Journal: Front Oncol Date: 2021-12-02 Impact factor: 6.244
Authors: Cecilia Barragán-Vargas; Jorge Montano-Frías; Germán Ávila Rosales; Carlos R Godínez-Reyes; Karina Acevedo-Whitehouse Journal: R Soc Open Sci Date: 2016-03-09 Impact factor: 2.963
Authors: Rafael Guerrero-Preston; Filipa Godoy-Vitorino; Anne Jedlicka; Arnold Rodríguez-Hilario; Herminio González; Jessica Bondy; Fahcina Lawson; Oluwasina Folawiyo; Christina Michailidi; Amanda Dziedzic; Rajagowthamee Thangavel; Tal Hadar; Maartje G Noordhuis; William Westra; Wayne Koch; David Sidransky Journal: Oncotarget Date: 2016-08-09
Authors: Ana Soriano-Lerma; Virginia Pérez-Carrasco; Manuel Sánchez-Marañón; Matilde Ortiz-González; Victoria Sánchez-Martín; Juan Gijón; José María Navarro-Mari; José Antonio García-Salcedo; Miguel Soriano Journal: Sci Rep Date: 2020-08-12 Impact factor: 4.379